

In re application of
Heinemann et al.
Application No.: 09/580,462
Page 4 of 9

Atty. Dkt. No.: SALK1590-3 (088802-2454)

REMARKS

In accordance with the present invention, there are provided nucleic acids encoding neuronal nicotinic acetylcholine receptor subunits and proteins encoded thereby. In particular, the invention relates to a family of novel mammalian neuronal nicotinic acetylcholine receptor subunits, for example, the beta2 subunit, which is a non-agonist binding subunit. Invention nucleic acids and the protein encoded thereby can be used for a variety of applications, *e.g.*, for drug design and screening. Moreover, transformed cell lines expressing specific receptor subunits can be produced in quantity for reproducible quantitative analysis of the effects of drugs on receptor functions.

Claims 34 and 38-44 are cancelled by this communication in efforts to reduce the issues and further prosecution.

It is respectfully submitted that entry of the amendments submitted herewith is proper because these amendments place the present application in condition for allowance or at a minimum, in better condition for appeal. It is further submitted that, upon entry of this amendment, fewer claims will be under consideration, claims 34 and 38-44 having been cancelled herein. Accordingly, entry of the amendments submitted herewith is respectfully requested.

After canceling the claims as set forth above, claims 7, 35-37, and 45-48 are now pending in this application. A detailed listing of all claims that are, or were, in the application, irrespective of whether a particular claim remains under examination in the application, is presented, beginning on page 2 of this paper under "Listing of Claims," with an appropriate defined status identifier.

In re application of
Heinemann et al.
Application No.: 09/580,462
Page 5 of 9

Atty. Dkt. No.: SALK1590-3 (088802-2454)

I. Objection

Claim 38

The objection to claim 38 under 37 CFR 1.75(c) as allegedly being of improper dependent form has been rendered moot by the cancellation of this claim.

II. 35 U.S.C. §112, 1st Paragraph (Written Description)

Claims 34 and 39-44

The rejection of claims 34 and 39-44 under U.S.C. §112, first paragraph as allegedly containing subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the art that Applicants had possession of the claimed invention, is respectfully traversed for at least the reasons already of record.

Specifically, Applicants respectfully disagree with the Examiner's assertion that the "specification does not describe a nucleic acid that is encompassed by the claims that does not encode the amino acid sequence presented in Figures 9A to 9C" (Office Action, pages 2-3, bridging paragraph). Contrary to the Examiner's assertion, the specification fully satisfies the written description requirement through disclosure of both a structural description and a functional description of beta2 subunits of neuronal acetylcholine receptors.

The specification provides a structural description of the beta2 subunit through presentation of an exemplary sequence of a beta2 subunit in Figures 9A, 9B, and 9C. Further, the specification describes at least four functional properties (e.g., ability to substitute for muscle beta1 subunit, not binding acetylcholine, etc.) of the beta2 subunit which distinguish it over other subunits of neuronal acetylcholine receptors. Indeed the subject claims require beta2 subunits

In re application of
Heinemann et al.
Application No.: 09/580,462
Page 6 of 9

Atty. Dkt. No.: SALK1590-3 (088802-2454)

defined with reference to both structural requirements and each of four specific functional properties. One of skill in the art would understand that the exemplary sequence of the beta2 subunit provided in the specification, in conjunction with specific functional properties provided in the specification, fully describes the claimed polynucleotides and distinguishes them from other polynucleotides encoding proteins that do not share these attributes. Therefore, it is respectfully submitted that the specification fully satisfies the written description requirement.

However, in order to reduce the issues and expedite prosecution, this rejection has been rendered moot by the cancellation of claims 34 and 39-44 by the present communication.

III. 35 U.S.C. §112, 1st Paragraph (Enablement)

Claims 34 and 39-44

The rejection of claims 34 and 39-44 under 35 U.S.C. §112, first paragraph as allegedly containing subject matter that was not described in the specification in such a way as to enable one skilled in the relevant art to make and/or use the invention is respectfully traversed. It is respectfully submitted that the specification fully enables the claimed invention.

Applicants respectfully disagree with the Examiner's assertion that the specification allegedly "does not provide the guidance that would be needed by an artisan to produce a functional neuronal acetylcholine receptor beta2 subunit protein having other than the naturally occurring amino acid sequence presented" (Office Action, page 3). Contrary to the Examiner's assertion, it is respectfully submitted that an artisan has been fully enabled, based on the functional requirements recited in the claims, the exemplary sequence of the beta2 subunit (presented in Figures 9A, 9B and 9C), and the experimental procedures disclosed in the specification, how to isolate and use polynucleotides which encode a beta2 subunit.

In re application of
Heinemann et al.
Application No.: 09/580,462
Page 7 of 9

Atty. Dkt. No.: SALK1590-3 (088802-2454)

However, in order to reduce the issues and expedite prosecution, this rejection has been rendered moot by the cancellation of claims 34 and 39-44 by the present communication.

III. 35 U.S.C. §112, 2nd Paragraph

Claims 34 and 39-44

The rejection of claims 34 and 39-44 under 35 U.S.C. §112, second paragraph as allegedly failing to point out and distinctly claim the subject matter that Applicants regard as the invention is respectfully traversed. Applicants respectfully disagree with the Examiner's assertion that the terms "high stringency conditions," "beta2," and "alpha2, alpha3, alpha4, alpha5, beta3 or beta4" are allegedly vague and indefinite. Contrary to the Examiner's assertion, each of these terms is well known in the art and/or are clearly described in the specification. Applicants reiterate their traversal of this rejection for at least the reasons already of record.

Specifically, with respect to claims 39-41, Applicants respectfully disagree with the Examiner's assertion that these claims are allegedly vague and indefinite for use of the phrase "under high stringency conditions" (Office Action, page 4). Contrary to the Examiner's assertion, it is respectfully submitted that the phrase "high stringency conditions" is well known in the art and is therefore, neither vague nor indefinite. Applicants previously cited two exemplary articles in support of this assertion (Response mailed March 15, 2004, page 9). These articles support the position that conditions of high stringency are well known to one of ordinary skill in the art and further, that one of ordinary skill in the art would recognize that optimization of those conditions is routine in achieving successful hybridization. Therefore, it is respectfully submitted that one of ordinary skill in the art would readily understand the phrase "high stringency conditions."

In re application of
Heinemann et al.
Application No.: 09/580,462
Page 8 of 9

Atty. Dkt. No.: SALK1590-3 (088802-2454)

With respect to claims 34 and 39-44, Applicants respectfully disagree with the Examiner's assertion that these claims are allegedly vague and indefinite for use of the term "beta2" (Office Action, page 4). Contrary to the Examiner's assertion, it is respectfully submitted that the specification provides a clear description of the beta2 subunit with reference to both structure and function. For example, the amino acid sequence and the DNA sequence of an exemplary beta2 subunit are presented in Figures 9A, 9B, and 9C. Further, functional properties of the beta2 subunit are described in the specification (see the replacement specification at, for example, page 1, paragraph [0003] and page 18, paragraph [0100]). Therefore, it is respectfully submitted that the description of the beta2 subunit provided in the specification supports the assertion that the term "beta2" is neither vague nor indefinite.

With respect to claims 42-44, Applicants respectfully disagree with the Examiner's assertion that these claims are allegedly vague and indefinite for use of the terms "alpha2, alpha3, alpha4, alpha5, beta3 or beta4" allegedly rendering it impossible to determine the metes and bounds of these claims (Office Action, page 4). Contrary to the Examiner's assertion, it is respectfully submitted that the specification discloses properties unique to each of these subunits, thus allowing one of skill in the art to determine the metes and bounds of these claims. For example, as cited previously, exemplary structural properties for each subunit are disclosed. See Figures 18A-18C (alpha2 subunit), Figure 13 (alpha3 subunit and alpha4 subunit), Figures 28A-28C (alpha5 subunit), Figure 23 (beta3 subunit), and Figures 27A-27C (beta4 subunit). It is therefore respectfully submitted that there is more than adequate description of these subunits to allow one of skill in the art to readily determine the metes and bounds of these claims.

However, in order to reduce the issues and expedite prosecution, this rejection has been rendered moot by the cancellation of claims 34 and 39-44 by the present communication.

In re application of
Heinemann et al.
Application No.: 09/580,462
Page 9 of 9

Atty. Dkt. No.: SALK1590-3 (088802-2454)

CONCLUSION

In view of the above amendments and remarks, the present application is respectfully submitted to be in condition for allowance. Accordingly, reconsideration and favorable action with respect to the pending claims is respectfully requested. In the event any issues remain to be resolved in view of this communication, the Examiner is invited to contact the undersigned at the number given below so that a prompt disposition of this application can be achieved.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872. If any extensions of time are needed for timely acceptance of papers submitted herewith, Applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 50-0872.

Respectfully submitted,

Date: April 8, 2005

By 

FOLEY & LARDNER LLP
Customer Number: 30542
Telephone: (858) 847-6711
Facsimile: (858) 792-6773

Stephen E. Reiter
Attorney for Applicant
Registration No. 31,192